

Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Non-selective Agents, Selective Agents), By Indication (Angina Pectoris, Heart Failure, High Blood Pressure, Others), By Drugs (Betaxolol, Acebutolol, Esmolol, Others), By Distribution Channel (Hospital Pharmacy; Retail Pharmacy; Online Pharmacy), By Application (Cardiac Diseases, Hypertension, Glaucoma, Others), By Region and Competition

<https://marketpublishers.com/r/B8D8D8924EE7EN.html>

Date: February 2024

Pages: 185

Price: US\$ 4,900.00 (Single User License)

ID: B8D8D8924EE7EN

Abstracts

Global Beta blockers Market was valued at USD 9.34 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.85% through 2029. According to the American College of Cardiology, Older adults are generally undertreated for high blood pressure, despite having the highest prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). Hypertension is a major modifiable risk factor for cardiovascular disease (CVD), and its prevalence and severity rise with age. According to the National Health and Nutrition Examination Survey (NHANES) in the United States, hypertension affects 70% of persons over 65. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is predicted to rise to 20% by 2050. Moreover, huge investment in R&D, high prevalence and incidence of cardiovascular diseases have increased the demand for beta blockers drugs due to which the market is expected to drive in the forecast period. The COVID-19 pandemic has moderately impacted healthcare systems and the market. Hypertension is one of the most common

morbidities in COVID-19. Beta-blockers are widely used as one of the most common antihypertensive agents. It reduces the risk of proarrhythmic by suppressing sympathetic-mediated triggers, the functioning re-entrant substrate, and the rates of the SA and AV nodes. In addition to this main benefit, as beta-adrenergic blockers, these drugs can block the gate of SARS-CoV-2 entry through negative regulation on the juxtaglomerular cells in the kidneys, reducing the activity of both arms of the RAAS pathway, thus lowering the ACE2 levels. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.

Key Market Drivers

Rising Cardiovascular Disease Prevalence is Driving the Global Beta blockers Market.

The global Beta blockers market is witnessing substantial growth, and one of the key driving factors is the rising prevalence of cardiovascular diseases. Cardiovascular diseases (CVD) are a leading cause of mortality and morbidity worldwide. Conditions such as hypertension, heart failure, and various arrhythmias affect millions of people, creating a significant healthcare burden. Beta blockers, a class of medications that block the effects of stress hormones like adrenaline, are widely used in the management of cardiovascular diseases. They work by reducing heart rate, blood pressure, and the heart's workload, ultimately improving its efficiency. This makes them valuable for treating conditions like hypertension, angina, and arrhythmias. The prevalence of hypertension, a major risk factor for CVD, continues to rise due to various factors, including sedentary lifestyles and poor dietary choices. In addition, an aging global population contributes to the growing prevalence of heart diseases, as older individuals are at higher risk. Heart failure, another common CVD, is a chronic condition that requires long-term management, often with the use of beta blockers.

Furthermore, beta blockers have proven efficacy in post-myocardial infarction care, reducing the risk of recurrent heart attacks. They are also employed in treating hypertrophic cardiomyopathy, an inherited condition causing the heart muscle to thicken. The rise in CVD cases, coupled with the effectiveness of beta blockers in managing these conditions, drives the global market's growth. As healthcare systems continue to emphasize preventive care and early intervention, beta blockers play a crucial role in mitigating the impact of cardiovascular diseases, thereby fueling their demand in the pharmaceutical market.

Hypertension management

The global Beta blockers market is experiencing a significant upsurge, with one of its major driving forces being the management of hypertension. Hypertension, or high blood pressure, is a pervasive and potentially life-threatening medical condition that affects a substantial portion of the world's population. It is a leading risk factor for cardiovascular diseases (CVD), stroke, and other health complications. Beta blockers, a class of medications, have established themselves as an essential component of hypertension management. These drugs work by blocking the effects of adrenaline and stress hormones on the cardiovascular system. By doing so, they reduce the heart rate and the force of contraction, subsequently lowering blood pressure. This makes beta blockers a highly effective choice for individuals with hypertension.

The prevalence of hypertension is on the rise globally, primarily due to various lifestyle factors such as poor dietary choices, sedentary behaviors, and increasing stress. Additionally, the aging population contributes to the growing burden of hypertension, as the risk of developing this condition increases with age. As healthcare systems worldwide place more emphasis on early diagnosis and management of hypertension to prevent associated complications, the demand for beta blockers has surged. Furthermore, hypertension often coexists with other cardiovascular conditions, such as angina, arrhythmias, and heart failure. Beta blockers are frequently used in combination therapy, making them a versatile choice for healthcare providers in managing complex cases. In recent years, beta blockers have demonstrated their effectiveness in not only lowering blood pressure but also improving overall cardiovascular outcomes. This has further solidified their role in hypertension management and overall CVD prevention.

As the global health community continues to address the growing prevalence of hypertension and the associated risks, the Beta blockers market is expected to maintain its robust growth. These medications are integral in the battle against hypertension and its adverse health effects, establishing them as a cornerstone in cardiovascular healthcare and driving the market's expansion.

Key Market Challenges

Generic competition leading to pricing pressure.

Generic competition poses a significant challenge for the Beta blockers market due to its impact on pricing. When patent protection expires for branded Beta blocker medications, generic versions enter the market at lower prices, leading to increased

pricing pressure. This can result in reduced revenue for pharmaceutical companies manufacturing the branded drugs. Patients, healthcare providers, and payers often opt for more cost-effective generic alternatives, affecting the market share and profitability of branded Beta blockers. To address this challenge, companies may explore strategies such as product differentiation, extended-release formulations, or combination therapies to maintain a competitive edge in the market.

Potential side effects affecting patient adherence.

The potential side effects associated with Beta blockers pose a significant challenge for the market by affecting patient adherence. While Beta blockers are effective in managing various cardiovascular conditions, they can lead to side effects such as fatigue, dizziness, and bradycardia. These side effects can discourage patients from adhering to their prescribed treatment regimens, leading to suboptimal outcomes. Non-adherence may result in inadequate control of blood pressure and other cardiovascular parameters. Pharmaceutical companies need to focus on developing Beta blockers with improved safety profiles and conducting patient education initiatives to mitigate these challenges and enhance patient adherence to treatment plans.

Evolving treatment guidelines

Evolving treatment guidelines in the field of cardiology present challenges for the Beta blockers market. As medical knowledge advances and new clinical evidence emerges, treatment guidelines for cardiovascular conditions are subject to change. This can impact the positioning and utilization of Beta blockers in patient management. Healthcare providers may opt for alternative medications or treatment modalities based on updated guidelines. As a result, Beta blockers may face increased competition from newer cardiovascular drugs and therapies. To address this challenge, pharmaceutical companies need to stay updated with evolving guidelines and invest in research to demonstrate the efficacy and safety of Beta blockers in the context of changing treatment recommendations.

Emerging alternative therapies impacting market dynamics.

The Beta blockers market faces challenges from emerging alternative therapies that impact its dynamics. As new treatment options, such as novel drugs and interventional procedures, become available, patients and healthcare providers may explore these alternatives. This can lead to increased competition and reduced market share for Beta blockers. To address this challenge, manufacturers of Beta blockers need to

demonstrate the advantages and clinical effectiveness of their products compared to emerging therapies. They must also invest in research and development to innovate and improve their offerings to remain competitive in the evolving landscape of cardiovascular disease management.

Key Market Trends

Personalized Medicine

Personalized Medicine is a prominent trend in the Beta blockers market as it involves tailoring treatment to individual patient characteristics. With advancements in genomics and biomarker identification, healthcare providers can determine the most suitable Beta blocker and dosage for a patient based on their genetic makeup, comorbidities, and lifestyle factors. This approach optimizes therapy, improves treatment outcomes, and minimizes side effects. Patients receive medications that are more effective for their specific condition, enhancing patient satisfaction and adherence. As the understanding of personalized medicine grows, it is expected to revolutionize the prescription and administration of Beta blockers, driving this trend in the market.

Combination Therapies

Combination Therapies represent a significant trend in the Beta blockers market. Healthcare providers are increasingly exploring combination treatments that involve Beta blockers along with other classes of medications to manage conditions like hypertension, heart failure, or arrhythmias more effectively. These combinations can enhance the therapeutic outcomes by targeting multiple aspects of the disease, leading to better control and fewer side effects. For instance, Beta blockers are often used in combination with ACE inhibitors or diuretics for heart failure management. This trend reflects the shift towards a more comprehensive and individualized approach to patient care, where combination therapies play a crucial role in optimizing treatment strategies and improving patient quality of life.

Focus on Generic Versions

The Beta blockers market is witnessing a growing focus on generic versions of these medications. As patents for some of the older, well-established Beta blockers have expired or are approaching expiration, generic pharmaceutical companies are entering the market. This trend increases competition, leading to the availability of more affordable generic options for patients and healthcare systems. Generic Beta blockers

offer cost-effective solutions for managing cardiovascular conditions, such as hypertension and angina. As a result, healthcare providers and patients are increasingly opting for these generic versions, contributing to the market's growth and accessibility while promoting cost-efficient healthcare practices.

Telemedicine Adoption

The Beta blockers market is experiencing a significant trend with the increasing adoption of telemedicine. Telemedicine, facilitated by advancements in technology and connectivity, enables patients to consult with healthcare providers remotely. This approach has gained prominence, especially in the wake of the COVID-19 pandemic. Patients can now receive medical consultations and prescriptions for Beta blockers through virtual appointments. Telemedicine not only enhances patient access to care but also promotes adherence to prescribed treatments. Additionally, it provides a convenient and efficient means of monitoring patients' response to Beta blockers, ensuring optimal management of cardiovascular conditions. The trend toward telemedicine is expected to continue shaping the Beta blockers market, offering greater convenience and accessibility to patients.

Research in Novel Beta Blockers

The Beta blockers market is witnessing a growing trend of research and development in novel Beta blockers. Pharmaceutical companies and researchers are exploring innovative formulations and compounds to enhance the efficacy and safety profile of Beta blockers. These efforts aim to develop Beta blockers with improved therapeutic outcomes and fewer side effects. With a focus on personalized medicine, novel Beta blockers are being tailored to individual patient needs. This trend not only expands treatment options but also contributes to the evolution of cardiovascular care. As research in novel Beta blockers advances, it is expected to drive market growth and provide better solutions for patients with cardiovascular conditions.

Segmental Insights

Indication Insights

Based on the indication, Angina pectoris, commonly known as angina, is a dominant condition driving the Beta blockers market. Beta blockers are a widely prescribed class of medications for the management of angina. They effectively reduce the heart's workload, oxygen demand, and blood pressure, making them valuable in alleviating

angina symptoms. As the prevalence of cardiovascular diseases, including angina, continues to rise due to factors such as sedentary lifestyles and dietary habits, the demand for Beta blockers remains high. Additionally, their use in post-myocardial infarction (heart attack) patients and other cardiac conditions contributes to their prominence. The effectiveness of Beta blockers in angina management positions them as a cornerstone therapy, supporting their dominance in the market.

Application Insights

Cardiac diseases, particularly conditions like hypertension and heart failure, play a dominant role in driving the Beta blockers market. Beta blockers are a key class of medications in the management of various cardiac ailments. They are highly effective in reducing heart rate, blood pressure, and the workload on the heart muscle, making them essential for controlling cardiovascular conditions. As the global burden of cardiac diseases continues to rise due to factors like lifestyle changes and an aging population, the demand for Beta blockers remains consistently high. Their proven benefits in enhancing heart function and reducing the risk of adverse cardiovascular events further solidify their dominance in the market.

Regional Insights

North America emerged as the dominant player in the global Beta blockers market in 2023, holding the largest market share in terms of value. North America is home to some of the world's most innovative medical technology companies and research institutions. This has resulted in the development of cutting-edge beta blockers that provide superior precision and patient safety. These advancements make the region a hub for the production and distribution of these devices. The United States and Canada both have rapidly aging populations. This demographic shift has led to an increase in the incidence of cardiovascular diseases, driving the demand for beta blockers. As individuals age, the likelihood of needing interventional cardiology procedures, which rely on these devices, also rises.

Key Market Players

Pfizer Inc

Novartis AG

Merck & Co. Inc

AstraZeneca PLC

Johnson and Johnson

Eli Lilly and Company

Sanofi SA

Bristol-Myers Squibb

Bayer AG

GlaxoSmithKline plc

Report Scope:

In this report, the Global Beta blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta blockers Market, By Type:

Non-selective Agents

Selective Agents

Beta blockers Market, By Indication:

Angina Pectoris

Heart Failure

High Blood Pressure

Others

Beta blockers Market, By Drugs:

Betaxolol

Acebutolol

Esmolol

Others

Beta blockers Market, By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Beta blockers Market, By Application:

Cardiac Diseases

Hypertension

Glaucoma

Others

Beta blockers Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Beta blockers Market.

Available Customizations:

Global Beta blockers market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

- 1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL BETA BLOCKERS MARKET OUTLOOK

- 4.1. Market Size & Forecast
 - 4.1.1. By Value
- 4.2. Market Share & Forecast
 - 4.2.1. By Type (Non-selective Agents, Selective Agents)
 - 4.2.2. By Indication (Angina Pectoris, Heart Failure, High Blood Pressure, Others)
 - 4.2.3. By Drugs (Betaxolol, Acebutolol, Esmolol, Others)
 - 4.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
 - 4.2.5. By Application (Cardiac Diseases, Hypertension, Glaucoma, Others)
 - 4.2.6. By Region

4.2.7. By Company (2023)

4.3. Market Map

4.3.1. By Type

4.3.2. By Indications

4.3.3. By Drugs

4.3.4. By Distribution Channel

4.3.5. By Application

4.3.6. By Region

5. ASIA PACIFIC BETA BLOCKERS MARKET OUTLOOK

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type

5.2.2. By Indications

5.2.3. By Drugs

5.2.4. By Distribution Channel

5.2.5. By Application

5.2.6. By Country

5.3. Asia Pacific: Country Analysis

5.3.1. China Beta blockers Market Outlook

5.3.1.1. Market Size & Forecast

5.3.1.1.1. By Value

5.3.1.2. Market Share & Forecast

5.3.1.2.1. By Type

5.3.1.2.2. By Indications

5.3.1.2.3. By Drugs

5.3.1.2.4. By Distribution Channel

5.3.1.2.5. By Application

5.3.2. India Beta blockers Market Outlook

5.3.2.1. Market Size & Forecast

5.3.2.1.1. By Value

5.3.2.2. Market Share & Forecast

5.3.2.2.1. By Type

5.3.2.2.2. By Indications

5.3.2.2.3. By Drugs

5.3.2.2.4. By Distribution Channel

5.3.2.2.5. By Application

5.3.3. Australia Beta blockers Market Outlook

5.3.3.1. Market Size & Forecast

5.3.3.1.1. By Value

5.3.3.2. Market Share & Forecast

5.3.3.2.1. By Type

5.3.3.2.2. By Indications

5.3.3.2.3. By Drugs

5.3.3.2.4. By Distribution Channel

5.3.3.2.5. By Application

5.3.4. Japan Beta blockers Market Outlook

5.3.4.1. Market Size & Forecast

5.3.4.1.1. By Value

5.3.4.2. Market Share & Forecast

5.3.4.2.1. By Type

5.3.4.2.2. By Indications

5.3.4.2.3. By Drugs

5.3.4.2.4. By Distribution Channel

5.3.4.2.5. By Application

5.3.5. South Korea Beta blockers Market Outlook

5.3.5.1. Market Size & Forecast

5.3.5.1.1. By Value

5.3.5.2. Market Share & Forecast

5.3.5.2.1. By Type

5.3.5.2.2. By Indications

5.3.5.2.3. By Drugs

5.3.5.2.4. By Distribution Channel

5.3.5.2.5. By Application

6. EUROPE BETA BLOCKERS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Indications

6.2.3. By Drugs

6.2.4. By Distribution Channel

6.2.5. By Application

6.2.6. By Country

6.3. Europe: Country Analysis

6.3.1. France Beta blockers Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By Indications

6.3.1.2.3. By Drugs

6.3.1.2.4. By Distribution Channel

6.3.1.2.5. By Application

6.3.2. Germany Beta blockers Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By Indications

6.3.2.2.3. By Drugs

6.3.2.2.4. By Distribution Channel

6.3.2.2.5. By Application

6.3.3. Spain Beta blockers Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type

6.3.3.2.2. By Indications

6.3.3.2.3. By Drugs

6.3.3.2.4. By Distribution Channel

6.3.3.2.5. By Application

6.3.4. Italy Beta blockers Market Outlook

6.3.4.1. Market Size & Forecast

6.3.4.1.1. By Value

6.3.4.2. Market Share & Forecast

6.3.4.2.1. By Type

6.3.4.2.2. By Indications

6.3.4.2.3. By Drugs

6.3.4.2.4. By Distribution Channel

6.3.4.2.5. By Application

6.3.5. United Kingdom Beta blockers Market Outlook

6.3.5.1. Market Size & Forecast

- 6.3.5.1.1. By Value
- 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Type
 - 6.3.5.2.2. By Indications
 - 6.3.5.2.3. By Drugs
 - 6.3.5.2.4. By Distribution Channel
 - 6.3.5.2.5. By Application

7. NORTH AMERICA BETA BLOCKERS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Type
 - 7.2.2. By Indications
 - 7.2.3. By Drugs
 - 7.2.4. By Distribution Channel
 - 7.2.5. By Application
 - 7.2.6. By Country
- 7.3. North America: Country Analysis
 - 7.3.1. United States Beta blockers Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Type
 - 7.3.1.2.2. By Indications
 - 7.3.1.2.3. By Drugs
 - 7.3.1.2.4. By Distribution Channel
 - 7.3.1.2.5. By Application
 - 7.3.2. Mexico Beta blockers Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Type
 - 7.3.2.2.2. By Indications
 - 7.3.2.2.3. By Drugs
 - 7.3.2.2.4. By Distribution Channel
 - 7.3.2.2.5. By Application
 - 7.3.3. Canada Beta blockers Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Indications

7.3.3.2.3. By Drugs

7.3.3.2.4. By Distribution Channel

7.3.3.2.5. By Application

8. SOUTH AMERICA BETA BLOCKERS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Indications

8.2.3. By Drugs

8.2.4. By Distribution Channel

8.2.5. By Application

8.2.6. By Country

8.3. South America: Country Analysis

8.3.1. Brazil Beta blockers Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By Indications

8.3.1.2.3. By Drugs

8.3.1.2.4. By Distribution Channel

8.3.1.2.5. By Application

8.3.2. Argentina Beta blockers Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By Indications

8.3.2.2.3. By Drugs

8.3.2.2.4. By Distribution Channel

8.3.2.2.5. By Application

8.3.3. Colombia Beta blockers Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By Indications

8.3.3.2.3. By Drugs

8.3.3.2.4. By Distribution Channel

8.3.3.2.5. By Application

9. MIDDLE EAST AND AFRICA BETA BLOCKERS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Indications

9.2.3. By Drugs

9.2.4. By Distribution Channel

9.2.5. By Application

9.2.6. By Country

9.3. MEA: Country Analysis

9.3.1. South Africa Beta blockers Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Indications

9.3.1.2.3. By Drugs

9.3.1.2.4. By Distribution Channel

9.3.1.2.5. By Application

9.3.2. Saudi Arabia Beta blockers Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Indications

9.3.2.2.3. By Drugs

9.3.2.2.4. By Distribution Channel

- 9.3.2.2.5. By Application
- 9.3.3. UAE Beta blockers Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Type
 - 9.3.3.2.2. By Indications
 - 9.3.3.2.3. By Drugs
 - 9.3.3.2.4. By Distribution Channel
 - 9.3.3.2.5. By Application

10. MARKET DYNAMICS

- 10.1. Drivers
- 10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

- 11.1. Recent Developments
- 11.2. Product Launches
- 11.3. Mergers & Acquisitions

12. GLOBAL BETA BLOCKERS MARKET: SWOT ANALYSIS

13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

- 14.1. Pfizer Inc
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Product & Services
 - 14.1.4. Financials (In case of listed)

- 14.1.5. Recent Developments
- 14.1.6. SWOT Analysis
- 14.2. Novartis AG
- 14.3. Merck & Co. Inc
- 14.4. AstraZeneca PLC
- 14.5. Johnson and Johnson
- 14.6. Eli Lilly and Company
- 14.7. Sanofi SA
- 14.8. Bristol-Myers Squibb
- 14.9. Bayer AG
- 14.10. GlaxoSmithKline plc

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Non-selective Agents, Selective Agents), By Indication (Angina Pectoris, Heart Failure, High Blood Pressure, Others), By Drugs (Betaxolol, Acebutolol, Esmolol, Others), By Distribution Channel (Hospital Pharmacy; Retail Pharmacy; Online Pharmacy), By Application (Cardiac Diseases, Hypertension, Glaucoma, Others), By Region and Competition

Product link: <https://marketpublishers.com/r/B8D8D8924EE7EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B8D8D8924EE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970